Otonomy, Inc. (OTIC)
(Delayed Data from NSDQ)
$2.82 USD
+0.02 (0.71%)
Updated May 3, 2019 03:59 PM ET
After-Market: $2.81 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[OTIC]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Industry: Medical - Drugs
Dropping Coverage Following Plan of Liquidation and Dissolution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 5.00
Industry: Medical - Drugs
OTO-313 Tinnitus Phase 2 Misses, Is Discontinued; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 12.50
Industry: Medical - Drugs
2Q22 Results; Potentially Transformational OTO-313 Tinnitus Phase 2 Data In August; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 12.50
Industry: Medical - Drugs
Efficacy Signals Piling Up; OTO-413 Hearing Loss POC Bolstered; OTO-313 Tinnitus Phase 2 Data Mid-Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 12.50
Industry: Medical - Drugs
4Q21: Tinnitus Phase 2 Over-Enrolled Well Ahead of Schedule; That and Hearing Loss Data by Mid-Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 12.50
Industry: Medical - Drugs
3Q21: Tinnitus and Hearing Loss Validation by Mid-2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 12.50
Industry: Medical - Drugs
Price: 25.00
Industry: Medical - Drugs
1Q21: Broad Neurotology Pipeline Advancing; Potential Gamechanging Tinnitus and Hearing Loss Data Mid-22;
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Otividex Phase 3 Misses; Lowering PT to $5.50; Stock Undervalues Earlier-Stage Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Otividex Pivotal Data This Month; Underappreciated Earlier Pipeline an Exciting Insurance Policy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Positive Hearing Loss POC; Broader Neurotology Pipeline Gaining Credibility; Otividex Phase 3 Data 1Q21; PT up to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
3Q20: On Cusp of Multiple Material Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
2Q20: Pipeline Advancing; Pivotal Otividex Data Within 6 Months as Early-Stage Pipeline Ripens
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Positive Tinnitus POC; New Otividex Stats Plan; Raise to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Only Slightly Behind Estimates; Undervalued With Cash Runway Through Multiple Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
COVID Delays Trials; Timing Update Expected Next Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
4Q19 Results Demonstrate Financial Discipline; Multiple Pipeline Catalysts Within Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
3Q19 Results; Deliberate Otividex Phase 3 Enrollment Means Data Slips a Quarter to 3Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Price: 75.00
|
|